KBC Group NV trimmed its stake in DaVita Inc. (NYSE:DVA - Free Report) by 14.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 270,195 shares of the company's stock after selling 45,960 shares during the period. KBC Group NV owned 0.34% of DaVita worth $41,332,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of DaVita by 291.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,388 shares of the company's stock worth $3,664,000 after buying an additional 18,164 shares during the period. Achmea Investment Management B.V. grew its stake in shares of DaVita by 71.0% during the 1st quarter. Achmea Investment Management B.V. now owns 25,793 shares of the company's stock valued at $3,946,000 after acquiring an additional 10,710 shares during the period. Board of the Pension Protection Fund increased its holdings in DaVita by 30.6% in the 1st quarter. Board of the Pension Protection Fund now owns 6,400 shares of the company's stock worth $979,000 after acquiring an additional 1,500 shares in the last quarter. Moran Wealth Management LLC raised its stake in DaVita by 6.2% during the 1st quarter. Moran Wealth Management LLC now owns 117,204 shares of the company's stock worth $17,929,000 after acquiring an additional 6,882 shares during the period. Finally, Asset Management One Co. Ltd. lifted its holdings in DaVita by 3.5% during the first quarter. Asset Management One Co. Ltd. now owns 20,063 shares of the company's stock valued at $3,069,000 after purchasing an additional 682 shares in the last quarter. 90.12% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Truist Financial reduced their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $164.50.
Check Out Our Latest Stock Analysis on DVA
DaVita Price Performance
DVA stock opened at $141.70 on Monday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. The company's fifty day moving average price is $139.46 and its 200-day moving average price is $149.46. DaVita Inc. has a one year low of $131.76 and a one year high of $179.60. The company has a market capitalization of $10.70 billion, a PE ratio of 14.04, a price-to-earnings-growth ratio of 0.98 and a beta of 1.11.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the previous year, the firm posted $2.26 EPS. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Stories
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
